Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 57Neoplasm Metastasis 3Stage II Prostate Adenocarcinoma 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Patient Preference 1Neoplasms 1Neoadjuvant Therapy 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Low Risk Prostate Cancer 1High-Risk and Oligometastatic Prostate Cancer 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Genital Diseases, Male 1Castration Levels of Testosterone 1Carcinoma, Small Cell 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Prostate Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 2prednylidene 1gallium 68 PSMA-11 1deltacortene 1apalutamide 1Prednisone 1Gonadotropin-Releasing Hormone 1BAY 86-7548 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Stage II Prostate Adenocarcinoma × apalutamide × Clear all
NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Rutgers, The State University of New Jersey

Phase 2 Active not recruiting
90 enrolled
Genitourinary

Stage II Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡